Clinical Trials in Seattle

Showing 1621-1640 of 8,049 trials

BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

NCT06611436

The BeCoMe-9 Study (BE-101-01) is a Phase 1/2, first in human, multi-center, open-label, dose-escalation study to evaluate the safety and clinical activity of a single intravenous (IV) dose of BE-101 in adults with moderately severe or severe Hemophilia B. Once infused, BE-101 is designed to engraft and continuously secrete FIX into the circulation to restore clinically meaningful levels of active FIX. BE-101 is an autologous (person's own cells) B Cell Medicine (BCM) which uses CRISPR/Cas9 gene editing to precisely insert human FIX gene into those cells.

Hemophilia BHemophilia B, Moderately Severe or Severe

Be Biopharma24 participantsStarted Dec 2024

Davis, California, United States • Ann Arbor, Michigan, United States • Minneapolis, Minnesota, United States +1 more locations

COMPLETEDPhase 1< 1 mile

Epigenetic Reprogramming in Relapse/Refractory AML

NCT03263936

This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).

Acute Myelogenous Leukemia

Therapeutic Advances in Childhood Leukemia Consortium37 participantsStarted Jul 2017

Los Angeles, California, United States • Orange, California, United States • San Francisco, California, United States +30 more locations

BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

Epigenetic Reprogramming in Relapse/Refractory AML

Find Trials by Condition in Seattle

Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain

PERIGON Pivotal Trial

Biliary Atresia Study in Infants and Children

Positive Peers Intervention Clinical Trial

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Longitudinal Study of Mitochondrial Hepatopathies

A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

SUBLOCADE Long-term Outcomes

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)